GlassScriptPhysician profile
Kaylyn E Amuso
NPI 1386206365
$6,477.99
in general payments reported to CMS, 2019-2025
40 companies · $3,419 in 2025
The $3,419 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $230 · 2023: $723 · 2024: $1,959 · 2025: $3,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,077 · Education: $24.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,076.69 |
| Education | $24.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.27 | 2022-2025 | |
| Lilly USA, LLC | $734.26 | 2023-2025 | Omvoh, Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $610.49 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.04 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $463.17 | 2021-2025 | Tremfya, Simponi, Stelara |
| Madrigal Pharmaceuticals | $344.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $184.57 | 2024-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $184.05 | 2024 | Minimed 780g |
| Novo Nordisk INC | $167.75 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $160.06 | 2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $155.19 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $152.07 | 2024-2025 | Dupixent |
| Genzyme Corporation | $144.98 | 2025 | |
| Sanofi-Aventis U.S. LLC | $141.23 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $133.14 | 2024-2025 | Iqirvo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.93 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Phathom Pharmaceuticals, INC. | $107.33 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $105.17 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $100.61 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $94.80 | 2023-2024 | Evenity, Prolia, Repatha |
| Celltrion USA INC. | $92.69 | 2025 | Vegzelma |
| Ibsa Pharma INC. | $72.12 | 2024-2025 | Tirosint, Licart, Flector |
| Aimmune Therapeutics, INC. | $67.33 | 2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $65.75 | 2024-2025 | |
| Gilead Sciences, INC. | $59.20 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.42 | 2023 | Farxiga |
| Corcept Therapeutics | $51.24 | 2023 | Korlym |
| Tandem Diabetes Care, INC. | $45.05 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $44.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $42.35 | 2024 | Strensiq |
| Pfizer INC. | $39.88 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $38.97 | 2024 | Recorlev |
| Braintree Laboratories, INC. | $24.77 | 2023 | Sutab |
| Recordati_rare_diseases_inc. | $20.44 | 2023 | Signifor Lar, Isturisa |
| Ferring Pharmaceuticals INC. | $20.14 | 2023 | Cimzia |
| Ironwood Pharmaceuticals, INC | $19.83 | 2023 | Linzess |
| Amneal Pharmaceuticals LLC | $19.04 | 2024 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $18.51 | 2024 | Crysvita |
| Cequr Corporation | $14.87 | 2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylyn Amuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.